Washington, DC Cancer researchers at Georgetown University's Lombardi Comprehensive Cancer Center have successfully tested a small, engineered antibody they say shuts down growth of human glioblastoma tumors in cell and animal studies. Glioblastoma is the deadliest of brain cancers; there is no effective treatment.
In the current online issue of the journal Oncogene, the researchers demonstrate how this antibody latches onto a receptor that studs the outside of glioblastoma cells, preventing a growth factor protein from binding to it and activating growth pathways in the tumors.
"We desperately need new treatments for glioblastoma, and these findings have given us hope that a new approach may be possible," says the study's lead investigator, Anton Wellstein, MD, PhD, a professor of oncology and pharmacology at Lombardi.
He adds that ALK receptors and the protein that binds to it, the growth factor pleiotrophin (PTN), are both also over-expressed in other difficult-to-treat cancers, such as melanoma and pancreatic tumors. "We have found that PTN drives metastasis of those cancers, suggesting that antibody treatment may be additionally useful in those cancers," Wellstein says.
Researchers at Lombardi/Georgetown University Medical Center have been working on this line of research since the mid 1980s, and the institution holds a patent on the "target" of the novel antibody a region on the ALK receptor. The patent also covers potential therapies. Before Wellstein joined Lombardi in 1989, he worked at the National Cancer Institute with other investigators hunting for growth factors that are secreted by cancer cells, and they eventually reported on PTN in 1992. He and his colleagues spent the next years finding PTN's receptor, which is ALK. They have since characterized the relationship between PTN and ALK, reporting in this study that many brain cancers overexpress PTN and ALK very similar to the developing brain. "When the brain is
'/>"/>
| Contact: Karen Mallet km463@georgetown.edu 215-514-9751 Georgetown University Medical Center Source:Eurekalert |
Related biology news :
1. In vitro antibody production enables HIV infection detection in window period -- key to safer blood
2. NEWSLETTER: Antibody Fragment Production Breakthrough with 2nd Generation EBA
3. Novel antibody prevents infection by hepatitis C virus
4. Mass Biologic Labs/UMass Med School and Medarex license C. difficile monoclonal antibody to Merck
5. Antibody key to treating variant CJD, scientists find
6. UC San Diego and Genentech scientists develop potentially disruptive antibody sequencing technology
7. ETH Zurich researchers develop antibody test
8. Bright lights: Mystery of glowing antibody solved by Scripps research scientists
9. Yale chemist receives NIH Young Investigator Award for antibody targeting
10. Reversing cognitive deficits: Injectable antibody may attack source of problem
11. UCLA researchers discover new molecular pathway for targeting cancer, disease
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |